A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs NY-ESO-1c259 TCR-transduced lymphocytes (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Adaptimmune
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2017 According to an Adaptimmune media release, as of May 18, 2017, 3 subjects have been enrolled in the study.